SNDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Syndax Pharmaceuticals Inc (SNDX) does not present a compelling buy opportunity for a beginner, long-term investor at this time. While the stock has some positive catalysts, the technical indicators, financial performance, and lack of strong trading signals suggest a cautious approach. The investor's impatience and unwillingness to wait for optimal entry points further support a 'hold' recommendation.
The stock's technical indicators are mixed. The MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 38.784, providing no clear signal. However, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 24.402, with resistance at 25.289 and support at 23.516.
The upcoming Phase 2 data for axatilimab in idiopathic pulmonary fibrosis and strong early launch metrics for Revuforj in leukemia provide potential upside.
The stock's recent trend indicates a 60% chance of declining -2.92% in the next week and -5.45% in the next month. Additionally, the financials show a significant net income drop of -27.77% YoY and EPS decline of -28.44% YoY, despite a strong revenue increase. No recent news or congress trading data to act as immediate catalysts.
In Q4 2025, revenue increased significantly by 794.90% YoY to $68.73M, but net income dropped by -27.77% YoY to -$68.01M, and EPS fell by -28.44% YoY to -0.78. Gross margin improved to 96.06%, up 7.64% YoY, indicating strong operational efficiency despite profitability challenges.
Analyst sentiment is positive overall, with multiple firms maintaining Buy or Outperform ratings. Price targets range from $28 to $57, reflecting confidence in the company's pipeline, particularly in idiopathic pulmonary fibrosis and leukemia treatments.
